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Pulmonary hypertension is an emerging complication of sickle cell anaemia with associated increased risk of mortality. In order to
evaluate the clinical and electrocardiographic ﬁndings in adult sickle-cell patients with pulmonary hypertension, a cross sectional
study was conducted on sixty two sickle cell anaemia patients and sixty two age and sex matched normal controls. Elevated
pulmonary artery pressures (PAP), deﬁned by PAP ≥ 30mmHg on echocardiography, was demonstrated in 41.9% of patients
with sickle cell anaemia and in 3.2% of the controls; χ2 = 26.571, P<0.001. Right ventricular hypertrophy, increased P-wave
duration,QTcinterval,andQTcdispersionweresigniﬁcantlyassociatedwithpulmonaryhypertension.Signiﬁcantcorrelationwas
found between mean PAP and (1) Frequency of crisis (Spearman correlation = 0.320; P = 0.011), (2) body mass index (Pearson’s
correlation = −0.297; P = 0.019), and (3) QTc interval (Pearson’s correlation 0.261; P = 0.040). Pulmonary hypertension in
adult sickle anaemia patients is associated with electrocardiographic evidence of right ventricular hypertrophy, and correlates
signiﬁcantly with frequency of vaso-occlusive crisis, and QTc interval. The observations by this study tend to suggest that these
parameters could be useful for early detection and prevention of pulmonary hypertension in patients with sickle cell anaemia.
1.Introduction
Pulmonary hypertension is an increasingly recognized com-
plication of sickle-cell anaemia and a risk factor for early
death [1–4]. Recurrent episodes of acute and subacute
pulmonary crises reﬂecting in situ sickling within the lung
has been postulated to be the primary event leading to
pulmonary hypertension. Haemolysis may participate in its
pathogenesis by limiting nitric oxide (NO) bioavailability
and producing vasculopathy [5, 6].
An initial study in Howard University, USA, using ech-
ocardiographic assessment of tricuspid valve regurgitant
jet velocity ≥2.5m/sec as diagnostic criteria, demonstrated
pulmonary hypertension in 32% of adult sickle-cell patients,
and the prevalence appeared to increase with age of the
patients [7]. In patients between 40 and 49 years old, the
prevalence was 40% and increased to 55–60% by age 50
and above. Other studies have documented prevalence rates
between 20 and 40% [4, 8–10].
Sickle-cell anaemia patients with pulmonary hyperten-
sion have a signiﬁcantly increased mortality rate compared
with patients without pulmonary hypertension. Sutton
and colleagues [4] reported 40% mortality rate in sickle-
cell patients with pulmonary hypertension at 22 months
after diagnosis (odd ratio 7.86; 95% conﬁdence interval
= 2.63–23.4) compared with sickle-cell patients without
pulmonary hypertension. Castro et al. [11] in a study of
34 adult sickle-cell patients who underwent right heart
catheterization for evaluation of pulmonary hypertension
found increased pulmonary artery pressure in 20 (58.8%)
on initial catheterization. During 23–45 months of follow
up, 11 of these 20 (55.0%) died compared with 3 of the 142 ISRN Hematology
without pulmonary hypertension (21.0%). Every 10mmHg
increase in mean pulmonary artery pressure was associated
with 1.7 increase in mortality (95% conﬁdence interval =
1.1–2.7; Cox proportional hazard model, P = 0.028). Little
is known about electrocardiographic ﬁndings in sickle-cell
patients with pulmonary hypertension. The study was aimed
at comparing the clinical and electrocardiographic ﬁndings
in sickle-cell anaemia patients with raised pulmonary artery
pressurewiththoseofpatientswithoutpulmonaryhyperten-
sion.
2.Methodology
2.1. Patients/Participants. The study was carried out in the
adult outpatient sickle-cell clinic and the Cardiac Centre
of the University of Nigeria Teaching Hospital (UNTH),
Enugu, Nigeria. The study subjects were drawn from adult
patients (age ≥ 18 years) [12], attending the adult sickle-
cell clinic of the hospital, who had haemoglobin genotype
SS on haemoglobin electrophoresis, were in steady state, and
consented to participate in the study. Steady state is deﬁned
as absence of any crisis in the preceding four weeks, absence
ofanysymptoms,orsignsattributabletoacuteillness.Atotal
of sixty two sickle-cell anaemia patients, and sixty two age-
and sex-matched normal controls were studied.
2.2. Study Procedure. All the subjects had clinical evaluation,
electrocardiographic and echocardiographic examinations.
Resting 12-lead electrocardiography was performed on all
subjects using cardioline Ar-600 model electrocardiography
machine at a paper speed of 25mm/s and standardized at
0.1mv/mm. A single observer analyzed the electrocardio-
gram. Measurements of the heart rate, cardiac axis, PR-
interval, QRS duration, and QTc interval were done in the
standard fashion. Heart rate correction of the QT interval
was performed using Bazett’s formula (QTc = QT/
√
RR)
[13]. The dispersion of P-wave, QRS, and QTc intervals
was measured manually under magnifying glass by the same
observer and was taken as the diﬀerence between the max-
imum and minimum values of each parameter on standard
12-lead electrocardiogram. Left ventricular hypertrophy on
electrocardiogram was based on Sokolow and Lyon voltage
criteria [14], while right ventricular hypertrophy was based
on the criteria described by Allenstein and Mori (dominant
o rt a l lR - w a v e so rR sp a t t e r ni naV R ,V 1,a n dV 2 with deep
S-wave in I, aVL, V5,a n dV 6)[ 15].
Echocardiography was done using Hewlett Packard
Sonos 2500 echocardiography machine with 3.7MHz trans-
ducer. Pulmonary artery ﬂow acceleration time was obtained
from a Doppler signal of the pulmonary ﬂow in the par-
asternal short-axis view at the aortic valve level and was
described as the time from onset to peak ﬂow velocity
[16]. The mean pulmonary artery pressure (mean PAP) was
calculated from the formula: [16] mean PAP (mm/Hg) =
90 − (0.62 × AT), where AT is the acceleration time of the
pulmonaryarteryﬂow.Pulmonaryhypertensionwasdeﬁned
as calculated mean pulmonary artery pressure ≥ 30mm/Hg
[4, 7].
2.3.EthicalConsideration. Ethicalclearanceforthestudywas
obtained from the Ethical Committee of the University of
Nigeria Teaching Hospital, Enugu, Nigeria. All the partici-
pants were treated in accordance with the requirements of
good clinical practice. The Declaration of Helsinki’s recom-
mendations for guiding physicians in biomedical research
involving human subjects were followed [17].
2.4.DataAnalysis. Datawerepresentedasmeans ±standard
deviation for continuous variables and as proportions for
categorical variables. Comparisons of continuous variables
between groups were made with independent Student’s
t-test. For discrete variables, distribution between groups
was compared with chi-square test and Fishers exact test as
appropriate (whereanexpectedcellislessthan5).Multivari-
ate Pearson’s correlation coeﬃcient was used to determine
the relations between clinical, electrocardiographic data and
mean pulmonary artery pressure. All statistical analyses were
carried out using the Statistical Packages for Social Sciences
(SPSS Inc., Chicago, Illinois) software version 11.0 and EPi-
Info version 3.4. Statistical tests with 2-tailed probability
values less than 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Baseline Clinical Characteristics. A total of 62 patients
and 62 control subjects were studied. The age, gender, and
anthropometric parameters of the patients and controls are
shown in Tables 1 and 2.
3.2. Mean Pulmonary Artery Pressure. Values for pulmonary
artery pressure in the patients and controls are shown in
Table 3. Mean pulmonary artery pressure was signiﬁcantly
higher in patients compared with controls. No signiﬁcant
age and gender diﬀerence in pulmonary artery pressure was
observed.
3.3. Prevalence of Pulmonary Hypertension. Elevated pul-
monary artery pressures (PAP) as deﬁned by PAP ≥
30mmHg was demonstrated in (26) 41.9% of patients with
sickle-cell anaemia and in (2) 3.2% of the controls; χ2 =
26.571, df = 1, P<0.001 (Figure 1).
3.4. Relationship between Clinical and ECG Parameters
and Pulmonary Hypertension. Right ventricular hypertrophy
was signiﬁcantly associated with pulmonary hypertension
(Table 4). The mean frequency of crisis per year was
higher in patients with pulmonary hypertension. History of
recurrent acute chest syndrome was noted in 75.9% of the
patients. P-wave duration, QTc interval, and QTc dispersion
were increased in patients with pulmonary hypertension
(Table 5).
SigniﬁcantcorrelationwasfoundbetweenmeanPAPand
(1) frequency of crisis (Spearman correlation = 0.320; P =
0.011), (2) body mass index (Pearson’s correlation = −0.297;
P = 0.019), and (3) QTc interval (Pearson’s correlation
0.261; P = 0.040), (Table 6).ISRN Hematology 3
Table 1: Age, gender, and anthropometric data.
parameters SCA Controls t-test P value
mean (SD) mean (SD)
Age (years) 28.27 (5.58) 28.37 (5.91) 0.987 0.924
Gender {frequency (%)}
Male 31 (50) 31 (50) 0.000 1.00a
Female 31 (50) 31 (50)
Total 62 62
Weight (kg) 54.97 (10.61) 67.35 (8.37) 7.20 <0.001∗
Height (m) 1.62 (0.14) 1.72 (0.07) 4.960 <0.001∗
Body surface area (m2) 1.62 (0.03) 1.78 (0.14) 3.723 <0.001∗
Body mass index (Kg/m2) 20.47 (2.73) 23.87 (3.22) 6.181 <0.001∗
∗Statistically signiﬁcant (2 sided); achi-square.
SCA—sickle-cell anaemia.
Table 2: Age distribution of patients and controls.
Age range Frequency χ2 df P value
Sickle-cell patients Controls
18–22 26 27
23–27 21 20
28–32 10 10
33–44 5 5
Total 62 62 0.043 3 0.999
Table 3: Mean pulmonary artery pressure in patients compared with controls.
Age range Mean PAP ±SD t-test df P value
Sickle-cell patients Controls
18–22 19.18 (9.79) 10.38 (6.99) 3.408 51 0.001∗
23–27 24.42 (6.68) 7.09 (6.02) 5.325 28 0.001∗
28–32 23.09 (7.07) 7.86 (4.61) 3.758 18 0.001∗
33–44 23.05 (4.96) 10.09 (6.25) 1.121 8 0.295
Total 21.80 (8.77) 8.60 (2.99) 6.785 118 0.001∗
∗Statistically signiﬁcant (2 sided), PAP = pulmonary artery pressure, and SD = standard deviation.
Table 4: Clinical and electrocardiographic parameters; association with pulmonary hypertension.
Parameters Frequency (%) χ2 P value
Increased PAP (n = 26) Normal PAP (n = 36)
Male gender 12 (46.15) 19 (52.78) 0.265 0.797
Female gender 14 (53.85) 17 (47.22)
Loud P2 23 (88.46) 29 (80.56) 0.4985a
LVH 12 (46.15) 32 (88.89) 13.382 <0.001∗
LAE 9 (34.62) 14 (38.89) 0.118 0.794
RVH 13 (50.00) 5 (13.89) 7.883 0.005∗
∗Statistically signiﬁcant (2 sided), a Fisher’s exact test, P2 = pulmonary component of second heart sound, LVH = left ventricular hypertrophy, LAE = left
atrial enlargement, and RVH = right ventricular hypertrophy.
4. Discussion
The prevalenceof pulmonary hypertension in adult Nigerian
sickle-cell anaemia patients in this study was 41.9%. This
value is slightly higher than previous report of 25% by Aliyu
et al. [10] in Northern Nigeria. However, in that study,
neither the mean PAP nor the mean age of the subjects was
stated.
Previous studies have relied on tricuspid regurgitant jet
velocity as an indirect estimate of PAP. This has resulted
in an underestimation of the prevalence of pulmonary
hypertension in sickle-cell anaemia patients. Results of right4 ISRN Hematology
Table 5: Comparison of clinical and electrocardiographic parameters in patients with normal and increased pulmonary pressure.
Parameters Values (mean SD) t-t e s t P value
Increased PAP Normal PAP
Age 25.08 (5.96) 23.64 (6.29) 1.011 0.316
Pulse rate 86.42 (6.99) 88 (5.19) 1.052 0.291
BMI 19.91 (2.11) 21.42 (3.23) 2.215 0.031∗
Mean crisis frequency/year 3.20 (1.52) 2.22 (1.19) 2.703 0.009∗
Systolic BP 121.00 (11.83) 119.28 (12.17) 0.556 0.580
Diastolic BP 63.00 (10.04) 66.50 (8.06) 1.521 0.133
MAP 79.12 (7.71) 83.26 (6.77) 1.284 0.204
Haematocrit 24.96 (2.73) 23.65 (3.34) 1.643 0.106
P-wave duration 152.3 (21.42) 109.4 (14.72) 9.354 0.0001∗
P-wave dispersion 62.3 (19.74) 64.4 (17.31) 0.460 0.647
PR-interval 197.7 (28.5) 196.4 (32.08) 0.165 0.869
QRS duration 88.5 (19.74) 87.2 (18.61) 0.252 0.802
QRS dispersion 52.3 (7.22) 52.2 (6.62) 0.016 0.987
QTc interval 433.8 (38.69) 398.6 (18.61) 4.760 0.0001∗
QTc dispersion 105.0 (23.24) 90.8 (18.54) 2.675 0.0096∗
∗Statistically signiﬁcant (2 sided), BMI = body mass index, and MAP = mean arterial blood pressure.
Table 6: Pulmonary artery pressure; correlation with some clinical and electrocardiographic parameters.
Parameters Patients Controls
r P value r P value
Age 0.149 0.249 −0.003 0.983
Freq. of crisis 0.308∗a 0.015 — —
BMI −0.297∗ 0.019 0.226 0.077
BSA −0.176 0.170 0.126 0.329
MAP −0.103 0.423 −0.156 0.225
Haematocrit 0.171 0.185 0.230 0.072
Heart rate 0.093 0.474 0.112 0.387
QTc 0.262∗ 0.040 0.250 0.050
∗Statistically signiﬁcant (2 sided), r = Pearson’s correlation coeﬃcient, P = probability value, a Spearman correlation, BMI = body mass index, BSA = body
surface area, and MAP = mean arterial blood pressure.
heart catheterization for evaluation of pulmonary artery
pressures in sickle-cell patients have shown prevalence rate
of 58.8% [11]. Autopsy studies suggest that up to 75% of
sickle-cell anaemia patients have histological evidence of
pulmonary arterial hypertension at the time of death [18].
Mean PAP derived from the echocardiographic estimation
of pulmonary artery ﬂow acceleration time in steady-state
patients as was used in this study has been shown to correlate
signiﬁcantly with values from cardiac catheterization [16].
Several studies have corroborated the role of vaso-
occlusive crisis and acute chest syndrome in initiating nitric
oxide depletion resulting in the pathological changes in
pulmonary hypertension [6, 19]. This study identiﬁed a
positive correlation between pulmonary artery pressure and
frequency of vaso-occlusive crisis.
Patients with pulmonary hypertension were found to
have reduced body mass index when compared with patients
without pulmonary hypertension. This diﬀerence could be
due to increased disease severity in patients with pulmonary
hypertension.
Recurrent insitu vaso-occlusive crisis in the pulmonary
vascular bed with resultant pulmonary hypertension and
right ventricular hypertrophy has been demonstrated in
sickle-cell disease patients [20]. This is in keeping with
the ﬁnding by this study of a signiﬁcantly increased preva-
lence of right ventricular hypertrophy in patients with
pulmonary hypertension. Right ventricular hypertrophy in
these patients explains the signiﬁcant positive correlation
between pulmonary artery pressure and QTc interval. The
signiﬁcance of increased P-wave duration and the spatial
dispersion of QTc-interval noted in this study in patients
with pulmonary hypertension are unclear. QTc dispersion
is a measure of the disparity among QTc intervals in
various electrocardiographic leads and reﬂects the variability
of myocardial repolarization [21]. This corroborates the
ﬁnding in a study by Akgul et al. in Turkey which recordedISRN Hematology 5
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Figure 1: Prevalence of increased pulmonary artery pressure in
patients and contols.
higher QTc dispersion in sickle-cell patients with pulmonary
hypertension [22].
5. Conclusion
Pulmonaryhypertensioninadultsickle-cellanaemiapatients
is signiﬁcantly associated with electrocardiographic evidence
of right ventricular hypertrophy, increased P-wave duration,
QTc interval, and QTc dispersion and correlates signiﬁcantly
with frequency of vaso-occlusive crisis and QTc interval. The
observations by this study tend to suggest that these param-
eters could be useful for early detection and prevention of
pulmonaryhypertensioninpatientswithsickle-cellanaemia.
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